Art

J-GLOBAL ID：201702286937409883   Reference number：17A1688903

Regorafenib induces adaptive resistance of colorectal cancer cells via inhibition of vascular endothelial growth factor receptor

レゴラフェニブは血管内皮成長因子受容体の阻害を介し結腸直腸癌細胞の適応耐性を誘導する

Author (8)： Tomida Chisato (Department of Physiological Nutrition, Institute of Medical Nutrition, University of Tokushima Graduate School) ,  Nagano Hikaru (Department of Physiological Nutrition, Institute of Medical Nutrition, University of Tokushima Graduate School) ,  Yamagishi Naoko (Department of Anatomy and Cell Biology, School of Medicine, Wakayama Medical University) ,  Uchida Takayuki (Department of Physiological Nutrition, Institute of Medical Nutrition, University of Tokushima Graduate School) ,  Ohno Ayako (Department of Physiological Nutrition, Institute of Medical Nutrition, University of Tokushima Graduate School) ,  Hirasaka Katsuya (Graduate school of Fisheries Science and Environmental Studies, Nagasaki University) ,  Nikawa Takeshi (Department of Physiological Nutrition, Institute of Medical Nutrition, University of Tokushima Graduate School) ,  Teshima-Kondo Shigetada (Department of Physiological Nutrition, Institute of Medical Nutrition, University of Tokushima Graduate School)
Material： Journal of Medical Investigation (Web)  (J Med Invest (Web))
Volume： 64  Issue： 3.4  Page： 262-265(J-STAGE)  Publication year： 2017 
JST Material Number： U0711A  ISSN： 1349-6867  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： *antitumor drug ,...
Semi thesaurus term： VEGF ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A1688903&from=J-GLOBAL&jstjournalNo=U0711A") }}

Author keywords (4)： angiogenesis inhibitor ,  regorafenib ,  VEGF-R ,  tumor cell aggressiveness

JST classification (2)： Basic research of antitumor(=antineoplastic)drugs  (GW16010A) ,  Receptors on cell membrane  (EF04030C)

Substance index (1)： Regorafenib

Reference (22)：

• 1. Bergers G, Hanahan D: Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603, 2008
• 2. Ellis LM, Reardon DA: Is there really a yin and yang to VEGF-targeted therapies? Lancet Oncol 11: 809-811, 2010
• 3. Jayson GC, Kerbel R, Ellis LM, Harris AL: Antiangiogenic therapy in oncology: current status and future directions. Lancet 388: 518-529, 2016
• 4. Meadows KL, Hurwitz HI: Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2: a006577, 2012
• 5. Zhao Y, Adjei AA: Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor. Oncologist 20: 660-673, 2015

Terms in the title (9)： レゴラフェニブ ,  血管内皮成長因子 ,  受容体 ,  阻害 ,  結腸直腸 ,  癌細胞 ,  適応 ,  耐性 ,  誘導